|
New tests available now are: Complement C4 genotype Bradykinin Prostaglandin D2 11 beta Prostaglandin F2 alpha Prostaglandin DM Mast cell activation markers RNA Polymerase III antibodies Extended myositis blot (additional antibodies available: TIF1g, MDA5, NXP2 and SAE1) Thrombospondin type-1 domain-containing 7A NMDAR (N-Methyl-D-Aspartate Receptor Antibodies) HLA B27 HLA DQ2 and HLA DQ8 ALEX Allergen Chip Faecal Immunochemical Test (FIT) Autoimmune Encephalitis Screen (NMDAR, CASPR2, LGI1, AMPAR1, AMPAR2 and GABA receptor antibodies) Myelin Oligodendrocyte Glycoprotein (MOG) antibodies Skin Antibodies: BP180, BP230, Desmoglein 1 (DSG1) and Desmoglein 3 (DSG3) Urine gliadin immunogenic peptides IgA Tissue transglutaminase 6 antibodies Voltage Gated Potassium Channel (VGKC) antibodies IgG Tissue transglutaminase 6 antibodies (Awaiting UKAS ETS outcome) Systemic Sclerosis Immunoblot (Scl-70, CENP-A, CENP-B, RPII, RP155, Fibrillarin (U3 RNP), NOR90, Th/To, PM-Scl75, Ku, PDGFR (platelet derived growth factor receptor), Ro52) (Awaiting UKAS ETS outcome) Newborn screening for SCID (flow cytometry panel) (Awaiting UKAS ETS outcome) New tests undergoing development: Rituximab quantitation and antibodies MUSK antibodies Ganglioside antibodies (extended panel)
|